Clinical trialPhase 4Unknown
The Effect of Application of TachoSil® in Pancreatoduodenectomy
The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy
- Outcome
- Outcome unknown
- Phase
- Phase 4
- Status
- Unknown
- Study type
- Interventional
- Start
- 27 February 2017
- Listed end
- May 2018
- Enrollment
- 126 participants
- Sites
- 1
- Primary outcomes
- Incidence of pancreatic fistula; Incidence of clinically relevant pancreatic fistula
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 1 September 2017
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Fibrinogen/thrombin-coated collagen patch (TachoSil®) is known to have the effect of strengthening tissue anastomosis and promoting suturing to prevent leakage. The purpose of this study is to compare the incidence of pancreatic fistula that is most crucial for surgical outcome and complications in pancreaticoduodenectomy with those of the control group and the TachoSil® apply group. Patients who were planned to undergo pancreaticoduodenectomy without a history of chronic pancreatitis are enrolled in this open-label, single-center, randomized, single-blind, phase 4 clinical trial.